Journal
CANCER CELL
Volume 40, Issue 1, Pages 36-+Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2021.11.002
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [R01CA112567, R01CA184836, R01CA208213]
- NIH Cancer Center support grant [P30CA016672]
- Cancer Prevention & Research Institute of Texas (CPRIT) [RP180734]
- METAVivor grants [56675, 58284]
Ask authors/readers for more resources
Antihistamines can improve survival in cancer patients by reversing T cell dysfunction through modulation of histamine receptor H1 (HRH1), thereby enhancing immunotherapy responses.
Reinvigoration of antitumor immunity remains an unmet challenge. Our retrospective analyses revealed that cancer patients who took antihistamines during immunotherapy treatment had significantly improved survival. We uncovered that histamine and histamine receptor H1 (HRH1) are frequently increased in the tumor microenvironment and induce T cell dysfunction. Mechanistically, HRH1-activated macrophages polarize toward an M2-like immunosuppressive phenotype with increased expression of the immune checkpoint VISTA, rendering T cells dysfunctional. HRH1 knockout or antihistamine treatment reverted macrophage immunosuppression, revitalized T cell cytotoxic function, and restored immunotherapy response. Allergy, via the histamine-HRH1 axis, facilitated tumor growth and induced immunotherapy resistance in mice and humans. Importantly, cancer patients with low plasma histamine levels had a more than tripled objective response rate to anti-PD-1 treatment compared with patients with high plasma histamine. Altogether, pre-existing allergy or high histamine levels in cancer patients can dampen immunotherapy responses and warrant prospectively exploring antihistamines as adjuvant agents for combinatorial immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available